| Filed On | Filing |
|---|---|
| 27 Jan 2020 |
8-K/A: Financial Statements and Exhibits
On November 21, 2019, Amgen Inc. (Amgen) completed the acquisition (the “Acquisition”) of certain assets and liabilities associated with the worldwide rights to Otezla® (apremilast) from Celgene Corporation (Celgene) for an aggregate pur... |
| 02 Feb 1995 |
8-K/A: Financial Statements and Exhibits
Amendment to Current Report Filed Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
Loading...